Co-Diagnostics Inc Dossier
Qualitative Analysis
Business overview
Co-Diagnostics, Inc. (Nasdaq: CODX) is a molecular diagnostics company that develops, manufactures, and markets state-of-the-art diagnostics technologies. The company's proprietary platform is built on its patented Co-Primersu0000 technology, which significantly reduces primer-dimer propagation to enhance the sensitivity and specificity of real-time PCR testing. Co-Diagnostics focuses on designing low-cost, highly efficient molecular testing solutions for infectious diseases, liquid biopsy, and agricultural applications. Its primary product pipeline centers around the Co-Dx PCR point-of-care and at-home platform, which includes the PCR Prou0000 instrument, mobile application, and single-use test cups.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Development, clinical evaluation, and regulatory clearance of the Co-Dx PCR Pro instrument, mobile app, and associated multiplex test menu (including COVID-19, Influenza A/B, RSV, TB, and HPV).
Expected impact: Establishment of a decentralized, high-accuracy molecular diagnostics ecosystem for point-of-care and at-home use.
Development of a dual-assay program featuring a pan-Ebola assay and a multiplex strain-differentiating assay, designed as the first blood-based pathogen test for the Co-Dx PCR Pro platform.
Expected impact: Expands the platform's capabilities beyond swab-based testing and positions the company to support global outbreak response and surveillance efforts.
Securing an exclusive 5-year distribution agreement with its longstanding partner in Mexico to distribute the Co-Dx PCR point-of-care platform and test kits.
Expected impact: Establishes a commercial footprint in Latin America ahead of required regulatory authorizations, leveraging a partner that has generated over $18 million in revenue for Co-Diagnostics since 2020.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Establishes localized manufacturing and distribution of Co-Dx PCR technologies across Saudi Arabia and 18 other MENA countries, aligning with Saudi Vision 2030.
Terms: Co-Diagnostics licenses its IP to the JV, while Arabian Eagle is responsible for funding and establishing the 14,400 square-foot manufacturing facility in Sudair Industrial City.
Serves as the company's manufacturing and commercial arm in South Asia. In March 2026, the territory was expanded to include Bangladesh, Pakistan, Nepal, and Sri Lanka, increasing the addressable market to an estimated $13 billion.
Terms: Joint venture structure with shared regional operational capabilities; currently exploring strategic alternatives including a potential SPAC transaction.